NCT00435084View on ClinicalTrials.gov

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

April 30, 2009

Conditions
B-cell Chronic Lymphocytic Leukemia
Interventions
DRUG

APO866

Trial Locations (4)

CF14 4 WX

Department of Heamtology, Cardiff and Vale NHS Trust, Cardiff

LS1 3EX

Department of Heamtology, Leeds General Infirmary, Leeds

EC1A 7BE

Department of Heamtology, Bart's and the London NHS Trust, London

NG5 1PB

Department of Heamtology, University Hospital of NHS Trust, Nottingham

Sponsors
All Listed Sponsors
lead

Valerio Therapeutics

INDUSTRY